Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427245 | 0.76 | ALDH1A1 (0.47) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| SCHEMBL29399235 | 0.75 | ALDH1A1 (1.00) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| SCHEMBL48945 | 0.75 | ALDH1A1 (1.00) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| SCHEMBL4412012 | 0.74 | MEN1 (0.39) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| Hydrochloric Acid SCHEMBL29494721 | 0.73 | ALDH1A1 (0.95) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| Ammonia Solution, Strong SCHEMBL2259240 | 0.73 | ALDH1A1 (0.95) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| Hydrochloric Acid SCHEMBL30913021 | 0.73 | ALDH1A1 (0.95) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| Methane SCHEMBL28975440 | 0.73 | ALDH1A1 (0.95) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| Hydrochloric Acid SCHEMBL30053031 | 0.73 | ALDH1A1 (0.95) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| Hydrochloric Acid SCHEMBL622811 | 0.73 | ALDH1A1 (0.95) | ALDH1A1HSD17B10CYP3A4TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1523475-B1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-23 | — | — | EP | disclosed |
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138414-B2 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-21 | — | — | US | disclosed |
| EP-1523475-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SLC5A2, CYP1A2, HBB | ALDH1A1 435/4885HSD17B10 1575/4885CYP3A4 12/4885 |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SLC5A2, CYP1B1, CYP2C19 | ALDH1A1 259/4885HSD17B10 1501/4885CYP3A4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.